Celyad Oncology SA (CLYYF)
USD 0.25
(0.0%)
USD 0.25
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 16.28 Million EUR | -17.42% |
| 2022 | 19.71 Million EUR | -75.34% |
| 2021 | 79.94 Million EUR | 20.97% |
| 2020 | 66.08 Million EUR | -26.44% |
| 2019 | 89.83 Million EUR | -4.73% |
| 2018 | 94.29 Million EUR | 21.48% |
| 2017 | 77.62 Million EUR | -44.08% |
| 2016 | 138.8 Million EUR | -12.99% |
| 2015 | 159.52 Million EUR | 262.75% |
| 2014 | 43.97 Million EUR | 35.79% |
| 2013 | 32.38 Million EUR | 135.6% |
| 2012 | 13.74 Million EUR | 99.87% |
| 2011 | 6.87 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 12.84 Million EUR | 0.0% |
| 2023 Q4 | 16.28 Million EUR | 0.0% |
| 2023 Q2 | 12.17 Million EUR | 0.0% |
| 2022 Q3 | - USD | N/A |
| 2022 FY | 19.71 Million EUR | -75.34% |
| 2022 Q1 | 69.21 Million EUR | -13.42% |
| 2022 Q2 | 63.14 Million EUR | -8.78% |
| 2022 Q4 | 19.71 Million EUR | 0.0% |
| 2021 Q1 | 62.1 Million EUR | -6.03% |
| 2021 FY | 79.94 Million EUR | 20.97% |
| 2021 Q4 | 79.94 Million EUR | 37.37% |
| 2021 Q3 | 58.19 Million EUR | -7.16% |
| 2021 Q2 | 62.68 Million EUR | 0.95% |
| 2020 FY | 66.08 Million EUR | -26.44% |
| 2020 Q4 | 66.08 Million EUR | 0.0% |
| 2020 Q2 | 75.76 Million EUR | 0.0% |
| 2019 Q4 | 89.83 Million EUR | 0.0% |
| 2019 FY | 89.83 Million EUR | -4.73% |
| 2019 Q2 | 81.35 Million EUR | 0.0% |
| 2018 Q2 | 109.05 Million EUR | 0.0% |
| 2018 Q4 | 94.29 Million EUR | 0.0% |
| 2018 FY | 94.29 Million EUR | 21.48% |
| 2017 Q4 | 77.62 Million EUR | 0.0% |
| 2017 Q2 | 120.29 Million EUR | 0.0% |
| 2017 FY | 77.62 Million EUR | -44.08% |
| 2016 Q4 | 138.8 Million EUR | 0.0% |
| 2016 FY | 138.8 Million EUR | -12.99% |
| 2016 Q2 | 139.99 Million EUR | 0.0% |
| 2015 Q4 | 159.52 Million EUR | 0.0% |
| 2015 FY | 159.52 Million EUR | 262.75% |
| 2015 Q2 | 183.29 Million EUR | 0.0% |
| 2014 Q4 | 43.97 Million EUR | 0.0% |
| 2014 FY | 43.97 Million EUR | 35.79% |
| 2014 Q2 | 51.8 Million EUR | 0.0% |
| 2013 FY | 32.38 Million EUR | 135.6% |
| 2013 Q4 | 32.38 Million EUR | 0.0% |
| 2013 Q2 | 15.04 Million EUR | 0.0% |
| 2012 FY | 13.74 Million EUR | 99.87% |
| 2012 Q4 | 13.74 Million EUR | 0.0% |
| 2011 FY | 6.87 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -4160.33% |
| CSL Limited | 38.02 Billion USD | 99.957% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 58.087% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -125.52% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -21224.358% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -54.273% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 87.496% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -22399.827% |
| Mesoblast Limited | 667.9 Million USD | 97.562% |
| Marizyme, Inc. | 22.01 Million USD | 26.042% |
| Genus plc | 1.02 Billion USD | 98.418% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -1098.657% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -3162.671% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -2496.81% |
| ContraFect Corporation | 20.67 Million USD | 21.263% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -4070.958% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | 31.33 Million USD | 48.037% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -292.714% |
| MultiCell Technologies, Inc. | 126.22 USD | -12899598.938% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -1632.701% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 87.33% |
| EV Biologics, Inc. | 431.71 Thousand USD | -3671.478% |
| Q BioMed Inc. | 3.51 Million USD | -363.147% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 53.717% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -6131.7% |
| Biomind Labs Inc. | 73.81 Thousand USD | -21956.652% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 45.754% |
| Skye Bioscience, Inc. | 11.94 Million USD | -36.36% |
| SQZ Biotechnologies Company | 107.18 Million USD | 84.81% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -492.863% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -731.483% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -1036.986% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -2268.339% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -2012.778% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 96.482% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -391.456% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -525.462% |
| GB Sciences, Inc. | 103.44 Thousand USD | -15640.222% |
| Alpha Cognition Inc. | 2.45 Million USD | -563.983% |
| argenx SE | 4.54 Billion USD | 99.642% |
| HST Global, Inc. | 1526.00 USD | -1066872.477% |
| Halberd Corporation | 10.13 Thousand USD | -160614.638% |
| Enzolytics Inc. | 361.7 Million USD | 95.499% |
| Resverlogix Corp. | 8.11 Million USD | -100.641% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -767.042% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 41.733% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 96.352% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 65.867% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -1023.793% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -2445.431% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -71371.841% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -81.939% |
| AVAX Technologies, Inc. | 7.37 Million USD | -120.708% |
| ONE Bio Corp. | 70.08 Million USD | 76.768% |
| Zenith Capital Corp. | 7410.00 USD | -219630.094% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.519% |
| Ember Therapeutics, Inc. | 184.00 USD | -8848813.043% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -4959.57% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -6129.626% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -1654.6% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -1548.031% |
| Agentix Corp. | 261.39 Thousand USD | -6128.959% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 2.3 Million USD | -606.659% |
| Helix BioMedix, Inc. | 3.02 Million USD | -438.233% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 69.105% |
| BioStem Technologies, Inc. | 14.56 Million USD | -11.825% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -28417.883% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -704748.485% |
| LadRx Corporation | 2.3 Million USD | -605.495% |
| Cell Source, Inc. | 195.17 Thousand USD | -8242.428% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -3288.152% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -4504.417% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -4504.417% |
| NovAccess Global Inc. | 62.24 Thousand USD | -26056.664% |
| Affymax, Inc. | 7.44 Million USD | -118.756% |
| Itoco Inc. | 1.4 Million USD | -1062.94% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -16921.232% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -15260.377% |
| CytoDyn Inc. | 11.13 Million USD | -46.21% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -11288.244% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -90962.64% |
| Qrons Inc. | 420.00 USD | -3876566.667% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -4123.923% |
| SYBLEU INC | 330.46 Thousand USD | -4826.952% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -2848.997% |
| Rebus Holdings, Inc. | 5000.00 USD | -325540.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -3876.826% |
| Mobile Lads Corp. | 52.00 USD | -31311438.462% |
| International Stem Cell Corporation | 5.39 Million USD | -202.078% |
| Bioxytran, Inc. | 137.63 Thousand USD | -11729.582% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -8.533% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 1.791% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -20510.127% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -1783.015% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -116.602% |
| Neutra Corp. | 2851.00 USD | -570997.86% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 49.756% |
| PureTech Health plc | 693.97 Million USD | 97.654% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -101.732% |
| IXICO plc | 15.84 Million USD | -2.765% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -96.595% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 84.242% |
| CSL Limited | 38.02 Billion USD | 99.957% |
| Cellectis S.A. | 333.99 Million USD | 95.125% |